H.C. Wainwright Starts Nabriva Therapeutics AG (NBRV) at Buy

September 8, 2016 8:01 AM EDT
Get Alerts NBRV Hot Sheet
Price: $8.37 +7.58%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade NBRV Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

H.C. Wainwright initiated coverage on Nabriva Therapeutics AG (NASDAQ: NBRV) with a Buy rating and a price target of $16. Analyst Ed Arce is positively on potential for successful readouts of the pivotal Phase 3 LEAP 1 (IV-to-oral) and LEAP 2 (oral only) studies.

Arce said, " ... despite the thorough in vitro data in CABP and the supportive translational data, we acknowledge that some investors may find reason for pause, given that no clinical trials of lefamulin in CABP patients have been conducted prior to the current, ongoing Phase 3 studies. Yet, we view key pre-clinical data (time-dependent killing via 24-hour AUC/MIC model, and substantial lung penetration and epithelial lining fluid (ELF) concentrations in animal and human studies) as strongly predictive of efficacy and supportive of pivotal testing. Importantly, the IV-to-oral LEAP 1 study is being conducted pursuant to a Special Protocol Assessment (SPA) with the FDA, which we view as offering some degree of validation for the trial. With QIDP and Fast Track status granted, and pivotal readouts of both Phase 3 studies expected in 2H17, we initiate coverage of NBRV with a Buy rating."

For an analyst ratings summary and ratings history on Nabriva Therapeutics AG click here. For more ratings news on Nabriva Therapeutics AG click here.

Shares of Nabriva Therapeutics AG closed at $7.92 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment